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Certain immune-driven mutations in HIV-1, such as those arising in p24Gag, decrease viral replicative capacity. However, the
intersubtype differences in the replicative consequences of such mutations have not been explored. In HIV-1 subtype B, the
p24Gag M250I mutation is a rare variant (0.6%) that is enriched among elite controllers (7.2%) (P  0.0005) and appears to be a
rare escape variant selected by HLA-B58 supertype alleles (P < 0.01). In contrast, in subtype C, it is a relatively common minor
polymorphic variant (10 to 15%) whose appearance is not associated with a particular HLA allele. Using site-directed mutant
viruses, we demonstrate that M250I reduces in vitro viral replicative capacity in both subtype B and subtype C sequences. How-
ever, whereas in subtype C downstream compensatory mutations at p24Gag codons 252 and 260 reduce the adverse effects of
M250I, fitness costs in subtype B appear difficult to restore. Indeed, patient-derived subtype B sequences harboring M250I ex-
hibited in vitro replicative defects, while those from subtype C did not. The structural implications of M250I were predicted by
protein modeling to be greater in subtype B versus C, providing a potential explanation for its lower frequency and enhanced
replicative defects in subtype B. In addition to accounting for genetic differences between HIV-1 subtypes, the design of cyto-
toxic-T-lymphocyte-based vaccines may need to account for differential effects of host-driven viral evolution on viral fitness.
Human leukocyte antigen (HLA) class I-restricted cytotoxic-T-lymphocyte (CTL) escape mutations that occur in conserved
HIV-1 regions can compromise the structural or functional integ-
rity of key viral proteins, affecting HIV-1 replication capacity. For
example, mutations associated with escape from HLA-B*57/B*58:
01-restricted responses to the TW10 epitope in p24Gag affect cy-
clophilin A binding ability (8), an important requirement for viral
replication (24, 37, 41). Vaccines designed to focus immune re-
sponses against regions of HIV-1 susceptible to deleterious muta-
tions may therefore represent a useful strategy to control viral
replication in vivo (2, 3, 18).
To date, studies of immune-driven alterations in viral fitness
have been undertaken predominantly on HIV-1 subtype B (7, 8,
11, 28, 32, 38, 39), the most common subtype in Western coun-
tries. Comparably fewer studies have examined subtype C (6, 21,
22, 48–50), despite the fact that it accounts for nearly 50% of
infections globally (13, 44). Furthermore, no comparative studies
of the replicative consequences of potential immune-driven mu-
tations in subtypes B versus C have been reported, despite the
relevance of this issue to the design of universal vaccines aimed at
attenuating the disease course (18). Indeed, comparative studies
of HIV-1 drug resistance and coreceptor tropism support critical
differences between HIV-1 subtype B and C with respect to in vitro
replicative capacity that have important implications for HIV
treatment and clinical monitoring (1, 20, 40, 51), suggesting that
similar intersubtype effects may be observed for immune-driven
viral polymorphisms.
The M250I mutation, located one residue downstream of the
TW10 epitope in p24Gag that is presented by numerous alleles of
the B58 supertype including B*57 and B*58:01 (52), is one of a
number of rare variants observed in HLA-B*57/B*58:01-express-
ing, subtype B-infected elite controllers, whose selection may con-
tribute to viral attenuation and immune control in these individ-
uals (33). In contrast, M250I appears to be a relatively common
minor polymorphism in HIV-1 subtype C (35, 36, 48), whose
relative fitness consequences were previously unknown. More-
over, M250I has been associated with lack of development of the
typical T242N escape mutation in HLA-B*57/B*58:01-positive
individuals in some (16, 28, 33) but not all (12, 14, 35) subtype B
and C cohorts, supporting its potential role as a polymorphism
that could serve to channel immune-driven HIV-1 evolution
down unconventional pathways (2, 3, 18).
In the present study, we explore the relative consequences of
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M250I, alone and in combination with other immune-driven and
putative compensatory mutations, in attenuating viral replication
in HIV-1 subtypes B and C. We also investigate the structural basis
for these defects. We confirm that M250I is very rare in HIV-1
subtype B, and that it is associated with substantial fitness costs
that are not easily compensated due to profound alterations in the
subtype B capsid structure. In contrast, M250I is more common in
subtype C, and its fitness impact may be rescued by the selection of
compensatory mutations. We also demonstrate additive fitness
consequences of T242N in combination with M250I in HIV-1
subtypes B and C. These results have implications for the design of
universal vaccines aimed at attenuating the disease course.
MATERIALS AND METHODS
Study subjects and data sources. (i) Subtype B chronic infection and
elite controllers cohort. The subtype B chronic infection cohort com-
prised 803 untreated individuals (median pVL of 5.1 log10 RNA copies/
ml, with an interquartile range [IQR] of 4.7 to 5.5 log10 RNA copies/ml,
and a median CD4 cell count of 273 cells/mm3 [IQR, 130 to 420 cells/l]).
Of these individuals, 762 (94.9%) represented the baseline (antiretroviral-
naive) cross-section of the British Columbia HOMER cohort, while the
remaining 41 (5.1%) represented chronically infected individuals re-
cruited from Massachusetts General Hospital who were untreated at the
time of sample collection (7). HLA class I typing and plasma HIV-1 RNA
gag sequencing were performed as described previously (7, 19). Construc-
tion of Gag-protease recombinant NL4-3 viruses expressing participant-
derived Gag-protease sequences, as well as evaluation of their replication
capacity, was performed as described previously (7) and below.
HLA class I types and plasma HIV-1 RNA gag sequences from a cohort
of 69 elite controllers (defined as chronically HIV-1-infected individuals
maintaining pVL at 50 copies RNA/ml in the absence of therapy) re-
cruited through Massachusetts General Hospital were also studied (de-
scribed in references 31 and 34).
(ii) Subtype C chronic infection cohort. The subtype C chronic infec-
tion cohort comprised 405 antiretroviral-naive chronically infected indi-
viduals from the Sinikithemba cohort in Durban, province of KwaZulu-
Natal, South Africa. The median viral load was 4.77 (IQR, 4.15 to 5.27)
log10 HIV RNA copies/ml, and the median CD4 count was 340 (IQR, 238
to 477) cells/l. HLA class I typing was performed as described previously
(26), and plasma HIV RNA gag sequencing was performed as described by
Wright et al. (48). Construction of Gag-protease recombinant NL4-3 vi-
ruses expressing participant-derived Gag-protease sequences, as well as
evaluation of their replication capacity, was performed as described in
reference 48 and below.
(iii) Subtype C longitudinal seroconverter cohort. The subtype C
longitudinal seroconverter cohort comprised 53 women enrolled in the
CAPRISA 002 observational cohort study, which was established to inves-
tigate the role of viral and immunological factors during acute/early sub-
type C infection on HIV-1 disease progression (47). The cohort includes
high-risk HIV-negative women monitored monthly for recent HIV-1 in-
fection using two rapid antibody tests and PCR (Roche Amplicor v1.5).
HIV-1 infection was confirmed using an enzyme immunoassay test.
Women were enrolled in the present study within 3 months of infection
from both the HIV negative cohort and other seroincident cohorts in
Durban, South Africa. The date of infection was estimated as the midpoint
between the last HIV-1-negative test and the first antibody-positive test,
or 14 days prior to the PCR-positive but antibody-negative date. Samples
were collected at enrollment, weekly for 3 weeks, fortnightly for 3 months,
monthly for a year, and quarterly thereafter. CD4 T cell counts were
assessed using a FACSCalibur flow cytometer, and viral loads were mea-
sured using a COBAS Amplicor HIV-1 Monitor Test v1.5 (Roche Diag-
nostics). The 53 individuals included in the present study represented
seroincident individuals monitored for 12 months postinfection. The me-
dian CD4 count and log viral load at 12 months postinfection (calcu-
lated as the average of the three time points closest to 12 months) were 416
cells/l (IQR, 341 to 563) and 4.43 log10 HIV RNA copies/ml (IQR, 3.35 to
4.93), respectively. The present study was approved by the relevant insti-
tutional review boards overseeing the above cohorts.
RNA isolation, RT-PCR, and viral sequencing. For the CAPRISA 002
cohort, viral sequencing was carried out as described previously (17).
RNA isolated from plasma samples by using a Magna-Pure compact nu-
cleic acid extractor (Roche, Mannheim, Germany) was reverse tran-
scribed using a Thermoscript reverse transcription (RT) kit (Invitrogen).
Limiting-dilution nested PCR was carried out by serial endpoint dilution
of the cDNA (34a). PCR products were either directly sequenced or
cloned using the pGEM-T Easy vector system (Promega). Sequencing was
carried out using an ABI Prism dye terminator cycle sequencing kit (Ap-
plied Biosystems). Chromatograms were assembled using ChromasPro
(www.technelysium.com.au/chromas.html) and aligned using CLUSTAL
W (46). PCR and sequencing primers used are listed in Table S1 in the
supplemental material.
HLA typing. For the CAPRISA 002 cohort, high-resolution (four-
digit) HLA typing was performed on all participants. DNA was extracted
from either peripheral blood mononuclear cells (PBMC) or granulocytes
using a Pel-Freez DNA isolation kit. HLA-A, -B, and -C typing was per-
formed by sequencing exons 2, 3, and 4 using Atria HLA-AlleleSeqr kits
(Abbott) or HLA-SBTexcellerator kits (Qiagen) and Assign-SBT v3.5
software (Conexio Genomics). Ambiguities resulting from polymor-
phisms outside the sequenced exons or identical heterozygote combina-
tions were resolved using sequence-specific primers or resolved statisti-
cally using a published computational HLA class I completion algorithm
trained on a data set of complete high-resolution HLA-A, -B, and -C types
from 13,000 individuals of known ethnicity (27; http://research
.microsoft.com/en-us/projects/bio/mbt.aspx#HLA-completion).
Viral replication assays of site-directed mutants and participant-
derived subtype B and C sequences (NL4-3 recombinant system). (i)
Generation of site-directed mutant viruses. HIV-1 NL4-3 (subtype B)
and consensus C (subtype C) p24 gag fragments were amplified using
100-bp-long primers CA_Chimeric Recomb F and CA_Chimeric Recomb
R, matching the NL4-3 sequence upstream and downstream of p24, re-
spectively (see Table S1 in the supplemental material). Amplicons were
cloned into the pGEM-T Easy vector. Site-directed mutagenesis was used
to introduce various mutations and combinations of mutations (T242N,
M250I, G248A/M250I, and T242N/M250I for subtype B and T242N and
M250I for subtype C) into the relevant p24 recombinant vectors using a
QuikChange II site-directed mutagenesis kit (Stratagene). To generate
recombinant NL4-3 viruses expressing the mutant p24 sequences, p24gag
was reamplified from the mutated recombinant pGEM-T Easy plasmids
using the primers described above.
The plasmid pNL4-3p24 was constructed by inserting unique
BstEII restriction sites at the 5= and 3= ends of p24Gag using a
QuikChange XL kit, followed by deletion of this region by BstEII di-
gestion (New England BioLabs). This plasmid was maintained using
Stbl3 Escherichia coli cells (Invitrogen). To generate recombinant vi-
ruses, 10 g of BstEII-linearized pNL4-3p24 plus 50 l of the above
amplicon (5 g) were mixed with 2.0  106 cells of a Tat-driven
green fluorescent protein (GFP) reporter T-cell line of CEM origin
(GXR 25 cells [9]) in 800 l of R10 medium (RPMI 1640 containing
10% fetal calf serum, 2 mM L-glutamine, 100 U of penicillin/ml, and
100 g of streptomycin/ml) and transfected by electroporation using a
Bio-Rad GenePulser II (exponential protocol: 300 V, 500 F). After
transfection, the cells were rested for 45 min at room temperature,
transferred to 25-mm3 flasks in 5 ml of R10 medium, and fed with 5
ml of R10 medium on day 5. GFP expression was monitored by flow
cytometry (FACSCalibur; BD Biosciences) and, once GFP expression
reached 15% among viable cells, supernatants containing the recom-
binant viruses were harvested, and aliquots were stored at 80°C.
The sequences of all recombinant virus stocks were verified via rese-
quencing.
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(ii) Generation of recombinant NL4-3 viruses expressing partici-
pant-derived sequences. The same approach was previously used to gen-
erate recombinant viruses expressing participant-derived HIV RNA Gag-
protease sequences from 803 chronically subtype B (7)- and 405
chronically subtype C (48)-infected individuals (data that were reana-
lyzed for the present study). Briefly, the Gag-protease region was RT-PCR
amplified from plasma HIV-1 RNA using sequence-specific primers, fol-
lowed by a second-round PCR using 100-bp-long polyacrylamide gel elec-
trophoresis-purified recombination primers designed to match the
NL4-3 sequence directly upstream of Gag and downstream of protease.
Amplicons were cotransfected with linearized pNL4-3gag-protease into
GXR T cells, and recombinant viruses were generated via homologous
recombination as described above and previously (7, 48).
(iii) Recombinant virus titers and replication capacity assays. Deter-
mination of virus titers and assessment of viral replication capacity of
site-directed mutant and participant-derived recombinant viruses was
performed as described previously (7, 48). Briefly, virus titers were deter-
mined by infecting GXR cells with chimeric virus stocks and measuring
GFP expression by flow cytometry. The titer data were used to adjust input
viral volumes in the subsequent replication capacity assay to obtain a
multiplicity of infection (MOI) of 0.003 on day 2. GFP expression was
monitored daily for a week. Replication capacity was expressed as the
slope of the natural log of the percentage of GFP-expressing cells between
days 3 and 6. This value was then divided by that of the appropriate
control strain (wild-type NL4-3 or consensus C), yielding a normalized
replication capacity value where 1.0 represented growth identical to that
of the control strain, and values of 1.0 and 1.0 represented growth that
was lower or higher than that of the control strain, respectively. Replica-
tion capacity assays of site-directed mutant viruses were performed in
triplicate in a single experiment, while recombinant viruses were assayed
in duplicate, and the results are reported as the average (mean) value.
Viral replication assays of subtype C site-directed mutants in a sub-
type C backbone (primary cell assay system). (i) Generation of molecu-
lar clones harboring Gag mutations in subtype C backbone. Specific gag
mutations were also engineered into a consensus gag sequence cloned into
an HIV-1 subtype C infectious molecular clone pBR246-F10 backbone
(provided by B. Hahn). The pBR246-F10 backbone contains HLA-B57/
B*58:01 escape variants that have been previously reported to reduce rep-
licative fitness (8, 28); therefore, we modified the backbone by replacing
the gag gene with a synthetic consensus subtype C gag gene, as follows. The
XhoI restriction site in the vector component of the original plasmid was
deleted by digestion with XhoI, followed by blunting with Klenow and
blunt-end ligation. A BssHII site at the 5= end of gag and a XhoI site 60
nucleotides downstream of the gag stop codon were engineered using a
QuikChange II site-directed mutagenesis kit. Quantitative PCR (qPCR)
primer sites were similarly introduced into nef (6). The consensus subtype
C full-length gag gene (www.hiv.lanl.gov) was synthesized (Integrated
DNA Technologies) and ligated into the pGEM-T Easy vector. The mu-
tations T242N, M250I, M250I/S252G/D260E, and T242N/M250I/S252G/
D260E were introduced through site-directed mutagenesis and confirmed
via DNA sequencing. The mutated genes were amplified using forward
and reverse primers harboring BssHII and XhoI restriction sites, respec-
tively, after which amplicons were digested and ligated into the modified
pBR246-F10 backbone. E. coli STBL3 cells (Invitrogen) were used to prop-
agate full-length proviral plasmids. In the subsequent experiments, the
recombinant pBR246-F10 molecular clone harboring consensus subtype
C Gag served as the control strain.
(ii) Generation of viral stocks of subtype C site-directed mutants.
Viral stocks were generated by transfection of HEK293T cells with 7.5 g
of plasmid DNA in Dulbecco modified Eagle medium (Gibco) supple-
mented with 10% fetal bovine serum (FBS; Atlantic Biologicals) using
Lipofectamine 2000 (Invitrogen). Supernatants were harvested 72 h after
transfection, and aliquots were stored at 80°C. HIV-1 p24 Capsid con-
centrations were quantified by a p24 enzyme-linked immunosorbent as-
say using the Vironostika HIV-1 Antigen MicroELISA system (bioMéri-
eux, Netherlands).
(iii) Viral replication assays in primary cells. PBMC isolated from
five healthy HIV-negative donors were CD8 depleted using Dyna-Beads
(Invitrogen). The PBMC were stimulated in RPMI 1640 supplemented
with 20% FBS, 5 mg of phytohemagglutinin (Sigma, St. Louis, MO)/ml,
and 20 U of interleukin-2 (Becton Dickinson Labware)/ml for 72 h prior
to infection. After 72 h, the PBMC were washed with 1 phosphate-
buffered saline supplemented with 1% (vol/vol) FBS (wash medium). A
total of 5.0  105 PBMC were inoculated with viral stocks (MOI 	 0.002)
in 1 ml of RPMI 1640 supplemented with 20% FBS and 20 U of interleu-
kin-2 (growth medium). After 24 h, the growth medium was removed,
PBMC were washed, and fresh growth medium was added. Then, 250 l
of supernatant was removed for qPCR analysis and replaced with an equal
volume of growth medium on days 2, 4, 6, 8, 10, and 12. Fresh PBMC were
added on day 6.
(iv) qPCR. RNA was extracted from 200 l of supernatant as described
above. cDNA was synthesized from 4 l of RNA using the Superscript III
RT-PCR kit (Invitrogen) in a total volume of 10 l. qPCR was carried out
as described earlier (6) on a LightCycler using the FastStart SYBR green kit
(Roche) in a 20-l reaction volume. Briefly, each reaction mixture con-
sisted of 10.4 l of distilled water, 1.6 l of MgCl2 (25 mM), 2 l each of
5 M stocks of WT-F and WT-R primers, 2 l of LightCycler SYBR green
mix, and 2 l of cDNA. The cycling conditions consisted of a 15-min
initial activation and denaturation step at 95°C, followed by 40 cycles of 15
s at 95°C and 1 min at 60°C, and a melting curve involving 1 min at 60°C,
followed by ramping to 95°C with continuous sampling. The quantifica-
tion standards consisted of the modified infectious molecular clone
pBR246-F10 linearized by BssHII digestion, followed by gel purification
and spectrophotometric copy number quantification.
Identification of amino acids covarying with M250I in participant-
derived subtype B and C sequences. Published phylogenetically in-
formed methods (14, 15) were used to identify HLA class I alleles associ-
ated with, and HIV-1 Gag amino acids significantly covarying with,
M250I in chronic subtype B (7) and subtype C (48) cohorts. Multiple
comparisons were addressed using q-values, the P value analogue of the
false discovery rate (FDR) (42). The FDR is the expected proportion of
false positives among results deemed significant at a given P value thresh-
old; for example, at a q  0.2, we expect 20% of the identified associations
to be false positives.
Conformational modeling of p24 helix 6 peptides. Conformational
modeling of peptide sequences was carried out using the program PEP-
FOLD (29, 45) via the PEP-FOLD standalone server (http://bioserv.rpbs
.univ-paris-diderot.fr/cgi-bin/PEP-FOLD). The HIV-1 consensus B p24
N-terminal domain nuclear magnetic resonance structure 1L6N (re-
trieved from the RCSB Protein Data Bank [www.pdb.org]) (43) was ed-
ited to include only residues from positions 242 to 252 and was used as a
structural template for modeling helix 6. Helix 6 stretches from positions
242 to 252 inclusive in the structure 1L6N. Helix 6 peptides from positions
242 to 252 were extracted from HIV-1 clade B and HIV-1 clade C consen-
sus sequences (www.hiv.lanl.gov) and submitted to PEP-FOLD for con-
formational modeling. PEP-FOLD reports the structure and energy of the
50 lowest energy conformations (i.e., the most stable) for each peptide
sequence that it models. We regarded this collection of 50 structures re-
ported by PEP-FOLD as a “cluster,” and we associated the pair of energy
terms—[a,b]—with each cluster. In the pair [a,b], “a” is the lowest value
in the cluster, and “b” is the highest energy value. The energy terms cal-
culated by PEP-FOLD are in kcal/mol. Predictions using PEP-FOLD al-
gorithms were qualitatively and semiquantitatively checked against pre-
dictions using the protein structure prediction server PSI-PRED (30; http:
//bioinf.cs.ucl.ac.uk/psipred).
Statistical analyses. Wilcoxon rank-sum tests were used to compare
viral loads and CD4 T-cell counts between pairs of group. The Fisher
exact test was used to compare differences in frequencies of the M250I
mutation between study cohorts and other dichotomous groups. Sta-
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tistical tests were implemented in GraphPad Prism 5.0 (GraphPad
Software, Inc.).
RESULTS
M250I is rare in subtype B and is associated with reduced fitness
in site-directed mutant and participant sequences. The Gag
M250I mutation was observed in only 5 of 803 (0.6%) chronically
subtype B-infected individuals (Fig. 1A). Of these, three harbored
an M/I mixture, while the remaining two harbored I as the sole
amino acid at this position (not shown). The median in vitro rep-
licative capacity of recombinant viruses expressing participant-
derived Gag/protease in a subtype B NL4-3 backbone was lower
among M250I-containing viruses (n 	 5) compared to those lack-
ing M250I (n 	 788), although this did not reach statistical signif-
icance (median of 0.91 versus 1.02, P 	 0.06; Fig. 1A). When
engineered alone into a NL4-3 backbone, M250I conferred a 22%
reduction in replication capacity compared to wild-type NL4-3
(Fig. 1B). To provide context, a site-directed NL4-3 mutant virus
expressing the well-characterized T242N mutation exhibited a 2%
reduction in replication capacity compared to wild-type NL4-3
(Fig. 1B).
Distribution and clinical correlates of M250I in subtype B
are also consistent with a fitness cost. M250I was previously de-
scribed as a rare mutation occurring in HIV-1 subtype B-infected
elite controllers (33), the same cohort analyzed in the present
study. Indeed, the frequency of this mutation was 12-fold higher
among elite controllers (5/69 [7.2%]) compared to chronically
subtype B-infected persons (5/803 [0.6%]) (Fisher exact test, P 	
0.0005; Fig. 2A). Moreover, in both subtype B-infected elite con-
trollers and chronically infected individuals, M250I was signifi-
cantly enriched in individuals expressing alleles of the HLA-B58
supertype (Fig. 2B). Whereas 5/26 (19.2%) of the elite controllers
expressing a B58-supertype allele were infected with viruses har-
boring M250I, the mutation was not observed in any of the 43 elite
controllers who did not express B58-supertype alleles (estimated
odds ratio [OR] of 22.3; Fisher exact test, P 	 0.0059; phylogeneti-
cally corrected P 	 0.0017). Similarly, while the mutation was
observed in 3/83 (3.6%) chronically infected individuals express-
ing a B58-supertype allele, it was only observed in 2/710 (0.025%)
individuals lacking such alleles (OR 13.3; Fisher exact test, P 	
0.0095; phylogenetically corrected P 	 0.004). A phylogenetically
corrected comparison of the estimated ORs of B58-supertype me-
diated selection of M250I in controllers (OR 	 22.3) versus
chronically infected individuals (OR 	 13.3) revealed that this
nearly 2-fold difference was statistically significant (P 	 0.017). Of
note, the five B58-supertype expressing controllers harboring
M250I were B*15:16/B*57:03, B*49:01/B*57:01, B*13:02/B*57:
01, B*15:17/B*57:01, and B*52:01/B*57:03, while the three B58-
supertype expressing individuals from the chronic cohort harbor-
ing M250I were B*15:01/B*57:01, B*08:01/B*58:01, and B*08:01/
B*58:01. Taken together, the results support M250I as a rare B58
supertype-associated polymorphism in subtype B, whose odds of
selection are nearly 2-fold higher among controllers compared to
chronically infected individuals harboring the relevant HLA al-
lele(s).
Furthermore, in our chronic subtype B cohort, a trend toward
lower plasma viral loads was observed in individuals infected with
viruses harboring the M250I mutation compared to individuals
infected with viruses lacking this mutation, although this was not
FIG 1 Subtype B replication capacity. (A and B) Normalized replication capacities of recombinant viruses expressing Gag-protease from subtype B chronically
infected patients carrying 250I (n 	 5) and 250M (n 	 788) (A) and NL4-3 site-directed mutants (T242N and M250I) (B). The error bars represent the standard
errors for triplicate measurements.
FIG 2 Distribution of M250I by cohort and HLA in subtype B. (A and B) Distribution of the M250I mutation between elite controllers and chronic subtype B
patients (A) and distribution between subjects with or without HLA-B58 supertype in the elite controller and chronic cohorts (B).
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statistically significant (median of 0.58 versus 5.08 log10 HIV RNA
copies/ml, P 	 0.089). CD4 counts were comparable between the
two groups (median of 300 versus 280; P 	 0.4) (see Fig. S1 in the
supplemental material).
In subtype C, M250I is associated with reduced fitness in site-
directed mutant, but not participant sequences. In subtype C,
the M250I frequency in both recently transmitted and chronic
viral sequences was considerably higher than in subtype B: 8/53
(15%) (median, 42 days postinfection) for recently transmitted
viruses and 41/405 (10%) for viruses from chronic infections. The
in vitro replicative capacities of NL4-3 derived recombinant vi-
ruses expressing subtype C Gag-protease sequences sampled dur-
ing chronic infections were comparable between M250I-contain-
ing (n 	 41) and non-M250I-containing (n 	 364) sequences
(median of 0.62 in both groups, P 	 0.95; Fig. 3A). However,
when introduced alone into a consensus subtype C p24gag (also in
an NL4-3 backbone), M250I conferred a 25% reduction in repli-
cation capacity compared to consensus C p24gag sequence (Fig.
3B). To provide context, a mutant NL4-3 virus expressing T242N
introduced into consensus C p24gag exhibited a 13% reduction in
replication capacity compared to consensus C p24gag sequence
(Fig. 3B).
Distribution and clinical correlates of M250I in subtype C
support a modest fitness cost. Analysis of longitudinal clonal Gag
sequences from our subtype C seroconverter cohort (median
[IQR] follow-up of 12.2 [11.7 to 31.1] months) revealed reversion
of M250I mutations to wild type in three of eight participants
harboring this polymorphism at their earliest time point (Fig. 4).
These three reversions occurred at 2.0 (subject CAP255), 11.3
(CAP261), and 22.4 (CAP277) months postinfection. In our sub-
type C seroconverter cohort at 12 months postinfection, we ob-
served modestly higher CD4 T-cell counts, although not statisti-
cally significant, among individuals harboring M250I (median of
480 versus 414 cells/l, P 	 0.08), whereas plasma viral loads were
comparable between the two groups (median of 3.73 versus 4.49
log10 HIV RNA copies/ml, P 	 0.15) (Fig. 5A and B). In our
subtype C chronic infection cohort, no differences in pVL and
CD4 counts were observed in individuals infected with M250I-
expressing viruses compared to individuals infected with viruses
lacking this mutation (median log10 HIV RNA copies/ml of 4.98
versus 4.78 [P 	 0.6] and median CD4 counts of 339 versus 340
cells/l [P 	 0.8], respectively) (Fig. 5C and D). Among chroni-
cally subtype C-infected individuals the M250I mutation was not
associated with the expression of any specific HLA class I alleles
(data not shown).
Covariation between M250I and other sites in p24 Gag. Fit-
ness costs of certain mutations can be fully or partially restored
through the selection of compensatory mutations at secondary
sites (22, 39, 49). To identify potential compensatory mutations
for M250I in subtypes B and C, we applied phylogenetically in-
formed methods (14, 15) to identify Gag amino acids covarying
with M250I in sequences from our chronic subtype B (7) and C
(48) cohorts. No significant M250I-associated amino acids were
identified in subtype B sequences at q  0.2 (data not shown),
which is likely due to the extreme rarity of this mutation in this
cohort. In contrast, in our chronic subtype C cohort, significant
covariation was detected between codon 250 and seven other Gag
sites, all of them in p24 (Table 1). Of these, codons 252 and 260
were the most statistically significant. Specifically, strong positive
associations were observed between M250I and both S252G and
D260E, suggesting that these may function as compensatory mu-
tations in a subtype C context. Independent analysis of our sub-
type C seroconverter cohort confirmed these covarying pathways,
although all q-values were 0.2 in this analysis due to the small
sample size (data not shown). We therefore hypothesized that
S252G and D260E represent compensatory mutations for M250I
in subtype C.
In addition, other amino acids potentially interacting with
M250I have been described, including a negative association be-
tween M250I and T242N in both subtypes B and C (16, 28, 33) and
a positive association between M250I and G248A in subtype B (16,
28, 33) (although other population-level studies have not reported
these [10, 14, 35]). Given the proximity of M250I to the B58 su-
pertype-restricted TW10 epitope and the association between this
supertype and M250I in subtype B, we therefore also assessed the
replicative consequences of M250I in combination with these mu-
tations.
S252G and D260E mutations partially restore the fitness of
subtype C M250I mutants. Our site-directed mutant experiments
described thus far featured mutants engineered into a consensus C
p24 sequence in an NL4-3 backbone. To confirm the effects of the
M250I mutation and to assess replicative costs associated with
putative compensatory and negatively associated mutations in a
full subtype C backbone, we engineered the T242N, M250I,
M250I/S252G/D260E (“IGE”), and T242N/M250I/S252G/D260E
(“NIGE”) mutations into consensus C p24Gag and inserted this
into the subtype C molecular clone backbone pBR246-F10 (see
Materials and Methods). Furthermore, to explore the replicative
costs of these mutations in a more biologically relevant context,
we assayed the resulting recombinant viruses in primary PBMC
FIG 3 Subtype C replication capacity. (A and B) Normalized replication capacities of recombinant viruses expressing Gag-protease from subtype C chronically
infected patients harboring M250I (n 	 41) and M250 (n 	 364) (A) and consensus subtype C p24 site-directed mutants (T242N and M250I) (B). The error bars
represent the standard errors for triplicate measurements.
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over 12 days in culture (see Materials and Methods). The replica-
tion curves of the mutants in the subtype C backbone over 12 days
in culture are shown in Fig. 6A. When the exponential slopes of
viral spread in Fig. 6A were calculated and normalized to those of
consensus C p24Gag, T242N- and M250I-containing viruses ex-
hibited 15 and 18% reductions, respectively, in replication com-
pared to the consensus C p24Gag control strain, values that were
consistent with the replication of these mutants when they were
engineered into the consensus C p24Gag/NL4-3 recombinant virus
backbone and cultured in a reporter cell line (Fig. 3B). The sub-
type C triple mutant virus M250I/S252G/D260E (IGE) exhibited
only an 8% reduction in replication compared to the control
strain, supporting the combination of S252G and D260E as com-
pensatory mutations for M250I (Fig. 6A and data not shown).
Notably, the quadruple mutant carrying the T242N/M250I/
S252G/D260E (“NIGE”) mutations exhibited a 31% reduction in
replication compared to the control strain (Fig. 6A and data not
shown), supporting a negative interaction between T242N and
M250I mutations in subtype C.
Examination of Gag sequences from our chronic subtype C
cohort with a “full” M250I substitution (i.e., no mixtures) re-
vealed that 30/36 (83%) harbored the full M250I/S252G/D260E
FIG 4 Gag sequences of M250I mutants from the acute subtype C cohort. An alignment of p24 sequences of viruses carrying M250I mutation at transmission
shows the reversion over time in three participants (red asterisk [CAP255, CAP261, and CAP277]). The B*57/B*58:01-restricted TW10 epitope is highlighted in
gray. The CypA binding loop is underlined. Site 250 is highlighted in yellow, whereas sites 252 and 260 are highlighted in green.
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(IGE) combination, 5/36 (14%) harbored M250I with either
S252G or D260E, and only one sequence (3%) harbored M250I in
the absence of either of these substitutions. Classification of par-
ticipant-derived sequences according to the number of compen-
satory mutations they possessed at codons 252 and 260 (0, 1, or 2)
revealed a dose-dependent increase in replication capacity over
this range. However, due to the presence of only one virus harbor-
ing M250I alone, it was not possible to perform a statistical test on
this overall trend (Fig. 6B). Moreover, of the viruses sampled from
the 30 individuals chronically infected with subtype C that har-
bored the IGE combination with no amino acid mixtures, only
one harbored the T242N mutation (data not shown), a finding
consistent with the quadruple T242N/M250I/S252G/D260E
(NIGE) combination being particularly detrimental (and thus
rare) in subtype C viruses.
Compensation for M250I appears difficult in subtype B vi-
ruses. As described above, no amino acids were identified to co-
vary significantly with M250I in our chronic subtype B cohort.
Furthermore, it was not relevant to introduce the putative subtype
C-specific compensatory mutations S252G and D260E into sub-
type B, since a G at position 252 is never observed in naturally
occurring subtype B sequences, and an E at position 260 is the
subtype B consensus. Previous reports, however, have suggested
that M250I may interact with certain HLA-B58-supertype associ-
FIG 5 M250I mutation and disease progression in subtype C infections. Comparisons of the plasma viral loads and CD4 T-cell counts between individuals
infected with M250I mutants and those without in the acute infection cohort (A and B) and in the chronic cohort (C and D) are shown. The viral loads and CD4
T-cell counts for the acute cohort were calculated as the means of three time points closest to 12 months postinfection.
TABLE 1 Covariation between codon 250 and other Gag sites in chronic subtype C sequencesa
Codon 250
Covarying
codon Association TT TF FT FF Total P q-value
250M 252G Negative 55 317 34 7 413 7.4E–09 8.0E–06
260D Positive 264 108 4 37 413 1.9E–08 8.0E–06
252S Positive 220 153 2 38 413 2.7E–07 7.0E–05
247M Negative 0 372 4 36 412 2.5E–05 5.0E–03
256V Positive 192 180 3 38 413 3.3E–05 5.0E–03
207D Positive 38 334 0 41 413 2.2E–04 3.0E–02
260E Negative 107 265 37 4 413 7.5E–04 8.0E–02
250I 252G Positive 33 6 55 318 412 1.4E–08 8.0E–06
260D Negative 4 36 264 110 414 1.4E–07 4.0E–05
252S Negative 2 37 220 154 413 5.4E–07 1.0E–04
256V Negative 3 37 192 181 413 5.0E–05 7.0E–03
247 M Positive 4 35 0 374 413 5.9E–05 8.0E–03
207D Negative 0 39 38 335 412 3.1E–04 3.0E–02
260E Positive 36 4 109 265 414 8.2E–04 8.0E–02
a TT, number of sequences with both codon 250 residueand covarying residue; TF, number of sequences with codon 250 residue butwithout covarying residue; FT, number of
sequences without codon 250 residuebut with covarying residue; FF, number of sequences with neither codon 250residue nor covarying residue.
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ated polymorphisms in the upstream TW10 epitope such as
T242N (for which a negative interaction had previously been sug-
gested with M250I [28]) and G248A (observed frequently in se-
quences harboring M250I [33]). We therefore investigated the
impact of these additional mutations on viral fitness when present
with M250I in a subtype B context. When engineered into an
NL4-3 backbone, the G248A/M250I double mutant exhibited 3%
higher replicative capacity compared to M250I alone and yet still
exhibited 19% lower replicative capacity compared to NL4-3 (Fig.
6C). These data suggest that G248A may only alleviate M250I-
associated fitness costs to a very minor extent, if any. The T242N/
M250I double-mutant virus had a replicative capacity 31% lower
than that of NL4-3, suggesting that previously described negative
associations between the two mutations are due to the severe fit-
ness cost of the T242N/M250I double mutation.
The M250I mutation probably destabilizes helix 6 of p24.
The p24Gag N-terminal hairpin (Gag codons 133 to 145), cyclo-
philin A binding loop (Gag codons 217 to 225), and helix 6 (Gag
codons 242 to 251), which includes the HLA-B58-supertype-re-
stricted TW10 epitope) are conformationally coupled (28). It is
believed that helix 6 stability is important in the binding of cyclo-
philin A by p24Gag (28) and that the modest replicative costs of
T242N are due in part to disruption of the interactions between
these p24Gag domains, thereby compromising the binding of
helix 6 to cyclophilin A. Given that M250I lies only one amino
acid downstream of TW10, we hypothesized that this mutation
may also affect the stability of p24Gag helix 6 and its associated
interactions. We therefore undertook conformational analysis
of published consensus subtype B and C p24Gag helix 6 peptide
sequences (www.hiv.lanl.gov) using PEP-FOLD (see Materials
and Methods).
The predicted conformations of naturally occurring subtype B
and C helix 6 peptides exhibited similar free energies (Table 2).
When M250I was introduced into these sequences in silico, the
predicted helical conformation of helix 6 was destabilized com-
pared to the cognate “wild-type” conformation for both subtypes,
but this effect was far more pronounced for subtype B compared
to subtype C (Table 2 and Fig. 7). The subtype B and C consensus
sequences differ at positions 248 and 252 (G248 versus A248 and
N252 versus S252 in subtype B versus subtype C), suggesting that,
in the context of M250I, either or both of these positions confer
the greater stability of subtype C helix 6 peptide compared to that
of subtype B. Further PEP-FOLD simulations on HIV-1 subtype B
helix peptides harboring the subtype C consensus residues A248
and S252 revealed that A248 had a major stabilizing influence on
helix 6 peptide and was predominantly responsible for minimiz-
ing the conformational differences between the wild-type and
M250I-containing subtype C helix 6 (see Table S2 in the supple-
mental material). This finding may in part explain the frequent
occurrence of G248A substitutions among subtype B M250I-con-
taining sequences, since the former may act to restabilize helix 6 in
a subtype B context.
FIG 6 M250I compensation in subtype C and B viruses. (A) Replication capacities of site-directed mutants (T242N, M250I, M250I/S252G/D260E [IGE] and
T242N/M250I/S252G/D260E [NIGE]) in a subtype C backbone showing the compensatory effect of the S252G and D260E mutations on the M250I mutant
(IGE). Pooled CD8-depleted PBMC were inoculated in duplicate at an MOI of 0.002, and viral spread was measured by qPCR. The error bars represent standard
errors for duplicate measurements. (B) Stratification of the subtype C Gag-protease replication capacities according to the number of the compensatory
mutations (S252G and D260E). (C) Replication capacities of subtype B NL4-3 site mutants showing the minimal compensatory effect of the G248A mutation.
The error bars represent the standard errors for triplicate measurements.
TABLE 2 Summary of helix 6 predictions by PEP-FOLD
Description of helix 6
peptide Sequence of helix 6 peptidea
Energy value (kcal/mol) in predicted cluster
Minimum Maximum
HIV-1 subtype B
Wild type TLQEQIGWMTN –11.878 –11.873
M250I variant TLQEQIGWITN –10.195 –10.116
HIV-1 subtype C
Wild type TLQEQIAWMTS –15.614 –15.610
M250I variant TLQEQIAWITS –14.863 –14.857
a The peptide spans amino acids 242 to 252. Amino acids 248, 250 and 252 are underscored.
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DISCUSSION
The extremely low frequency (0.6%) of M250I in chronic subtype
B sequences renders it challenging to draw firm conclusions re-
garding its provenance and fitness impact in vivo. Despite this,
multiple lines of evidence support a fitness cost in this subtype.
First, even when it is present, M250I tends to occur as a mixture
alongside M250 (i.e., it rarely achieves fixation in vivo), suggesting
an inherent incompatibility between it and the subtype B genetic
background. Second, patient-derived sequences harboring this
mutation exhibit modestly (albeit not significantly) lower replica-
tion capacities and lower viral loads than those harboring M250.
In both chronic (7) and controller (33) subtype B cohorts, M250I
was enriched among individuals expressing an HLA allele belong-
ing to the B58 supertype. Moreover, odds of B58 supertype-me-
diated selection of M250I was nearly 2-fold higher among control-
lers compared to chronically infected individuals, supporting
M250I as a rare B58-supertype associated escape variant preferen-
tially selected in elite controllers. The mechanism(s) behind this
differential selection remain unclear; in addition, our observa-
tions are in contrast to those of a previous report of M250I occur-
ring in a minority of hypermutated proviral (but not plasma HIV
RNA or intact proviral) sequences from seven HLA-B*57-ex-
pressing elite controllers (5). Elite controller sequences from the
present study are indeed derived from HIV RNA (a DNase step
was used during RNA extraction to eliminate proviral DNA con-
tamination [31]); as such, the enrichment and differential selec-
tion of M250I among elite controllers merits follow-up in inde-
pendent cohorts.
The rarity of M250I (along with the fact that it is most often
observed as an M/I mixture at position 250) may also explain its
lack of identification in population-level studies of HLA-associ-
ated polymorphisms in subtype B (10, 25) and the difficulty of
identifying (10, 25) potential compensatory mutations using
computational approaches. Nevertheless, based on the observa-
tion that the upstream G248A mutation (a well-characterized
B58-supertype-associated polymorphism [10, 25]) is often pres-
ent, along with M250I in elite controller sequences (33), we at-
tempted to evaluate G248A as a putative compensatory mutation
for M250I. Introduction of G248A alleviated M250I-associated
replicative defects only to a very modest extent (3%), if at all.
Although the lack of statistical power due to the rarity of M250I
represents a limitation of our analysis, results nevertheless suggest
that M250I-associated fitness costs are not easily rescued via com-
pensatory mutations in subtype B.
In contrast, in subtype C, M250I appears to represent a minor
(10%) polymorphic variant where fitness costs can be alleviated
through selection of compensatory mutations in vivo. First, indi-
viduals harboring M250I-containing viruses tended to have mod-
estly (albeit not statistically significantly) higher CD4 counts dur-
ing early (but not chronic) subtype C infection. Second, reversion
of M250I mutations were observed in 40% of cases following
transmission. Most notably, despite the M250I mutation confer-
ring an 18% reduction in replicative capacity when introduced
alone into a subtype C backbone, no differences in replication
were observed between M250I-containing and non-M250I-con-
taining subtype C viruses sampled during chronic infection. Fur-
thermore, computational analyses identified two p24Gag polymor-
phisms —S252G and D260E—strongly covarying with M250I
that restored the replicative capacity of M250I mutants from 82 to
92% of control strain levels when engineered into a subtype C
backbone. The observation that all but one M250I-containing pa-
tient sequences sampled during chronic infection harbored one or
both of these compensatory mutations and that the replication
capacities of these were higher than the sequence harboring
M250I alone was also suggestive of M250I-associated fitness costs
being recouped by compensatory mutations.
We also investigated previous reports of a potential negative
interaction between the T242N and M250I mutations reported in
some (16) but not all (7, 10, 35, 48) cohorts. There were differ-
ences that may be attributable to variation in host/viral or other
characteristics between cohorts and/or geographic regions. Of in-
terest, the replicative capacity of the T242N/M250I double mutant
was 13% lower than that of the M250I single mutant, thus provid-
FIG 7 Effect of M250I mutation on p24 helix 6. (A) N-terminal domain of p24 (PDB ID 1AK4 [23]) showing helix 6 (in color) and positions 248 (cyan) and 250
(red). (B) Conformation predicted for the wild-type HIV-1 subtype B helix 6 peptide. (C) Conformation predicted for the M250I variant. (D) Conformation
predicted for the wild-type HIV-1 subtype C helix 6 peptide. (E) Conformation predicted for the M250I variant. In all panels, the residue at position 248 is shown
in cyan and that at position 250 is shown in red. Stick representations are also shown at residue positions 248 and 250. In panels B and C, the helix 6 peptide has
a glycine at position 248, and in panels D and E it has an alanine. The images were rendered using Pymol (www.pymol.org).
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ing a mechanism to explain the proposed negative interaction, if
indeed one exists.
In silico analysis of the structural consequences of M250I re-
vealed that it likely has a severe destabilizing effect on the subtype
B p24Gag helix 6 structure that may be partially alleviated by the
B58-supertype-associated mutation G248A. Notably, although
G248A may partially stabilize helix 6 in subtype B, its ability to
compensate for the replicative fitness costs of M250I appears to be
marginal at best. In subtype C, the modest effect of M250I on helix
6 structure can be attributed to the stabilizing effects of the alanine
residue at position 248, which is the consensus amino acid at this
position in subtype C. This provides a possible explanation for the
substantially higher frequency of the M250I mutation in subtype
C sequences compared to subtype B sequences. The host factor(s),
if any, driving the higher frequencies of M250I in subtype C se-
quences remain unknown but may be revealed through more sta-
tistically powerful analyses of larger subtype C cohorts or compar-
ative analyses of subtype C cohorts from different geographical
regions (similar to those undertaken for subtype B) (4).
In conclusion, M250I in HIV-1 subtype B appears to be a rare
immune-driven mutation with fitness consequences, but in
HIV-1 subtype C it is a relatively innocuous circulating polymor-
phism that is not selected by any known HLA alleles. Analysis of
the structural basis for these observations suggests that M250I has
a greater destabilizing effect on the subtype B p24gag helix 6 struc-
ture compared to subtype C, yielding greater replicative fitness
costs. It is possible that M250I in subtype B reduces the ability of
p24 to bind host factor cyclophilin A (21, 26); however, further
studies will be required to explore this potential mechanism. Our
data suggest CTL-based vaccines targeting functionally con-
strained HIV-1 regions that aim to drive viral evolution down
fitness-attenuating pathways may need to account for intersub-
type differences in the specific mutations selected under immune
pressure and their relative impact on viral fitness.
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